You are here:
Toxicoproteomics and its applications to human health risk assessment
Citation:
GE, Y., R. D. OWEN, AND J. PRESTON. Toxicoproteomics and its applications to human health risk assessment. Proteomics-Clinical Applications. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 1(12):1613-1624, (2007).
Impact/Purpose:
This review provides a comprehensive overview of toxicoproteomics from human health risk assessment perspectives.
Description:
What is the study? Toxicoproteomics is the use of proteomic technologies to better understand environmental and genetic factors, toxic mechanisms and modes of action in response to acute exposure to toxicants and in the long-term development of diseases caused or influenced by these exposures. Use of toxicoproteomic technologies to identify key biochemical pathways, mechanisms and biomarkers of exposure and toxicity will decrease the uncertainties that are associated with human health risk assessments. This review provides a comprehensive overview of toxicoproteomics from human health risk assessment perspectives. Why was it done? This is the first review article on toxicoproteomics and its application to human health risk assessment. Key toxicoproteomic technologies such as 2D gel-based proteomic technologies and toxicoproteomic approaches are described, and present examples of applications of these technologies and methodologies in the risk assessment context are presented. The discussion includes a focus on challenges and future directions. What is the impact to the field and the agency? This is the first review article on toxicoproteomics and its application to human health risk assessment. It pointed out directions and provided solutions for risk assessment¬oriented toxicoproteomic research. It could also serve as a guideline for EPA's proteomic research. So this review article will be an excellent addition to the literatures in both proteomics and human health risk assessment.
